Table 2.

Clinical and pathological features of metastatic RCC patients

Baseline characteristics Tot (n)	21
Median age (range) – years	61 (36–70)
Sex, n (%) Male Female	19 (90.5%) 2 (9.5%)
Histological classification Clear cell Other	21 (100%) 0 (0%)
Prior nephrectomy Yes No	5 (23.8%) 16 (76.2%)
No. of evaluable disease sites, n (%) ≤2 ≥3	4 (19.1%) 17 (80.9%)
Site of metastasis Lung only Lung + others	6 (28.6%) 15 (71.4)
Site of metastasis, individual Lung Lymph node Liver Bone Pancreas SNC	10 (47.6%) 11 (52.4%) 6 (28.6%) 5 (23.8%) 1 (4.7%) 4 (19%)
IMDC Prognostic Risk Group, n (%) Favorable Intermediate Poor	6 (28.6%) 15 (71.4%) 0 (0%)
Best response to nivolumab treatment
Complete response (CR)	1 (4.7%)
Partial response (PR) Stable disease (SD) Progressive disease (PD)	9 (42.9%) 10 (47.7%) 1 (4.7%)
Median duration of response (range) – months	14 (3–28)